Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980248 · ClinicalTrials.gov registry record · Phase 1
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04980248 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04980248, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.
Interventions
- BIOLOGICAL ALXN1850
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04980248
The ClinicalTrials.gov registry entry for NCT04980248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN1850 is the first listed.
NCT04980248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04980248 about?
NCT04980248 is a clinical study titled "Study of ALXN1850 in Participants With Hypophosphatasia (HPP)". This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.
What is the current status of trial NCT04980248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-09-28. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT04980248?
The interventions under investigation include: ALXN1850 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04980248?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.